Investigating the substrate specificity of the master kinase LKB1 and the pharmacological targeting of its substrate NUAK2 to treat cancers

研究主激酶 LKB1 的底物特异性及其底物​​ NUAK2 治疗癌症的药理学靶向

• 批准号: nhmrc : GNT1143335
• 负责人: Dr Kelan Chen
• 金额: $ 38.48万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigating-substrate-specificity-treat-cancers/1348521
• 关键词: Investigating; substrate; specificity; master; kinase

Kinases are key regulators of cell signaling and emerging drug targets. LKB1 kinase specifically activates a set of substrates to modulate cellular processes, and its substrate NUAK2 is a novel target for cancer. I will elucidate the structural basis of how LKB1 recognizes its substrates and develop inhibitors targeting LKB1-NUAK2 interaction for cancer treatment. My project will provide key insights into kinase-dependent signaling and establish a new framework for therapeutics development.

激酶是细胞信号传导和新兴药物靶点的关键调节因子。LKB1激酶特异性激活一组底物来调节细胞过程，其底物NUAK2是癌症的新靶点。我将阐明LKB1如何识别其底物的结构基础，并开发针对LKB1- nuak2相互作用的癌症治疗抑制剂。我的项目将为激酶依赖性信号传导提供关键见解，并为治疗开发建立新的框架。